Type: Cervical and gynaecological cancers
Research has indicated that the HPV vaccine could have further-reaching benefits than preventing HPV and cervical cancer.
Professor Anna deFazio wants to create a new treatment pathway so a patient with ovarian cancer can be screened at the time of diagnosis to determine the molecular profile of her cancer.
Over 62 million deaths could be averted if HPV vaccination, cervical screening and access to cancer treatment services can be rapidly scaled by worldwide.
Our researchers have investigated the potential for cervical cancer to be eliminated as a public health problem globally.
Professor De Fazio’s team investigated a rare and treatment-resistant subtype of ovarian cancer. Their approach has a better chance of predicting which treatments will work.
This project would be a significant step forward in development of personalised treatments and should improve survival for this aggressive cancer.
Research shows Australia is on track to become the first country in the world to eliminate cervical cancer as a public health problem.
Our researchers are providing crucial evidence to support prevention strategies both in Australia and around the world.
A study by Cancer Council NSW has found that rates of vulvar cancer have been increasing significantly
from the late 1980s to the mid-2000s.
This world-first trial of cervical screening in an HPV-vaccinated population, will further increase our knowledge of Australia’s new cervical cancer screening program.